The expression of PD-L1 (Ventana SP142) in HER2-positive breast cancer and its relationship with clinicopathological characteristics

被引：0
|
作者：
Zhang, Ningning [1 ]
Liu, Yueping [1 ]
机构：
[1] Hebei Med Univ, Hosp 4, Dept Pathol, Shijiazhuang, Hebei, Peoples R China
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
breast cancer; HER2-positive; PD-L1; TILs;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS2-30
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Ventana PD-L1 (SP142) Assay
    McGill, Rachel
    Michail, Ramez
    Miller, Brianne
    Milton, Erica
    Musyoka, Agnes
    Musyoka, Rhoda
    O'Conner, Jada
    Ogunnaike, Morenike
    Omeke, Soteria
    Franklin, Gallop
    Honeywell, Marlon S.
    US PHARMACIST, 2022, 47 (10) : 42 - 44
  • [2] Study on the heterogeneity of expression of PD-L1 (Ventana SP142) in breast cancer in space and time
    He, J.
    Liu, Y.
    VIRCHOWS ARCHIV, 2021, 479 (SUPPL 1) : S70 - S70
  • [3] Clinicopathological values of PD-L1 expression in HER2-positive breast cancer
    Sasagu Kurozumi
    Kenichi Inoue
    Hiroshi Matsumoto
    Takaaki Fujii
    Jun Horiguchi
    Tetsunari Oyama
    Masafumi Kurosumi
    Ken Shirabe
    Scientific Reports, 9
  • [4] Clinicopathological values of PD-L1 expression in HER2-positive breast cancer
    Kurozumi, Sasagu
    Inoue, Kenichi
    Matsumoto, Hiroshi
    Fujii, Takaaki
    Horiguchi, Jun
    Oyama, Tetsunari
    Kurosumi, Masafumi
    Shirabe, Ken
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [5] Expression of PD-L1 using SP142 CDx in triple negative breast cancer
    Al-Jussani, Ghada N.
    Dabbagh, Tamara Z.
    Al-Rimawi, Dalia
    Sughayer, Maher A.
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2021, 51
  • [6] PD-L1 (SP142) Expression in Primary and Recurrent/Metastatic Triple-Negative Breast Cancers and Its Clinicopathological Significance
    Han, Eun Kyung
    Woo, Ji Won
    Suh, Koung Jin
    Kim, Se Hyun
    Kim, Jee Hyun
    Park, So Yeon
    CANCER RESEARCH AND TREATMENT, 2024, 56 (02): : 557 - 566
  • [7] PD-1 and PD-L1 Expression in HER2-Positive Breast Carcinomas
    Ubago, Julianne M.
    Larson, Alexandra
    Eghtesad, Mansooreh
    Blanco, Luis Z.
    Pincus, Jennifer
    Siziopikou, Kalliopi P.
    LABORATORY INVESTIGATION, 2017, 97 : 75A - 75A
  • [8] PD-1 and PD-L1 Expression in HER2-Positive Breast Carcinomas
    Ubago, Julianne M.
    Larson, Alexandra
    Eghtesad, Mansooreh
    Blanco, Luis Z.
    Pincus, Jennifer
    Siziopikou, Kalliopi P.
    MODERN PATHOLOGY, 2017, 30 : 75A - 75A
  • [9] Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
    Sung Gwe Ahn
    Seon-Kyu Kim
    Jonathan H. Shepherd
    Yoon Jin Cha
    Soong June Bae
    Chungyeul Kim
    Joon Jeong
    Charles M. Perou
    Breast Cancer Research and Treatment, 2021, 188 : 165 - 178
  • [10] Comparison of SP142 (Ventana) and SP263 (Ventana) assays to test PD-L1 expression in metastatic cancer patients to be treated with immune checkpoint inhibitors.
    Oyan, Basak
    Sonmez, Ozlem
    Yazar, Aziz
    Teomet, Mehmet
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345